Kolon Q1 2026 Operating Profit Surges 158%…TG-C Phase 3 Trial On Track

Consolidated revenue KRW 1.5188 trillion (+7.7% YoY), operating profit KRW 98.8 billion (+158% YoY), significant improvement
Parent company net profit turned positive at KRW 13.6 billion (vs. loss of KRW 16.0 billion in prior year)
Debt ratio 204.2%, slightly improved from 207.3% at year-end 2025
Subsidiary Kolon TissueGene's TG-C (cell gene therapy for osteoarthritis) completed US Phase 3 patient enrollment, preparing BLA submission to FDA
Issued KRW 60 billion exchangeable bonds to acquire additional stake in Kolon TissueGene
Subsidiary Kolon Global completed absorption merger of Kolon LSI and M.O.D. (Dec 2025)
Kolon Mobility Group became wholly-owned subsidiary via stock swap (Dec 2025)
Kolon Industry completed merger with Kolon Enp (Apr 2026)
Multiple construction defect lawsuits ongoing but financial impact limited
Dividend policy: target at least 40% of separate net income (excl. one-off items)